Mariette C, Piessen G, Lamblin A, Mirabel X, Adenis A, Triboulet J P
Department of Digestive and General Surgery, University Hospital Claude Huriez, Centre Hospitalier Régional Universitaire, France.
Br J Surg. 2006 Sep;93(9):1077-83. doi: 10.1002/bjs.5358.
The aim of this study was to determine the effect of neoadjuvant radiochemotherapy (RCT) on postoperative complications and survival after surgery for locally advanced oesophageal squamous cell carcinoma.
Postoperative course and survival were compared in 144 patients who had neoadjuvant RCT and 80 control patients who had surgery alone for locally advanced oesophageal squamous cell carcinoma (radiological stage T3, N0 or N1, M0).
The two groups were comparable in terms of American Society of Anesthesiologists grade, age, sex, weight loss, tumour location, presence of lymph node metastasis and surgical approach. Postoperative mortality rates were 6.3 and 9 per cent (P=0.481), with morbidity rates of 40.3 and 41 percent (P=0.887) in the RCT and control group respectively. Complete resection (R0) rates were 74.3 and 48 percent respectively (P<0.001). Significant downstaging was observed in the RCT group (P<0.001), with 16.0 percent of patients having a complete pathological response. Median survival was 29 versus 15 months, and the 5-year survival rate 37 versus 17 percent (P=0.002) in RCT and control groups respectively.
Neoadjuvant RCT significantly enhanced R0 resection and survival rates in patients with stage T3 oesophageal squamous cell carcinoma, with no increase in postoperative mortality and morbidity rates.
本研究旨在确定新辅助放化疗(RCT)对局部晚期食管鳞状细胞癌手术后并发症及生存情况的影响。
比较了144例接受新辅助RCT的患者与80例仅接受手术治疗的局部晚期食管鳞状细胞癌(放射学分期为T3、N0或N1、M0)对照患者的术后病程及生存情况。
两组在麻醉医师协会分级、年龄、性别、体重减轻、肿瘤位置、淋巴结转移情况及手术方式方面具有可比性。RCT组和对照组的术后死亡率分别为6.3%和9%(P = 0.481),发病率分别为40.3%和41%(P = 0.887)。R0切除率分别为74.3%和48%(P < 0.001)。RCT组观察到显著的降期(P < 0.001),16.0%的患者出现完全病理缓解。RCT组和对照组的中位生存期分别为29个月和15个月,5年生存率分别为37%和17%(P = 0.002)。
新辅助RCT显著提高了T3期食管鳞状细胞癌患者的R0切除率和生存率,且未增加术后死亡率和发病率。